News about 'clinical trials'

21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
17 Apr 2018
A new laborartory resource handbook was published in March 2018 to support TB clinical trials. The authors and summary of the handbook are below. Please click here for a link to the full handbook. Authors Kathleen Eisenach, University of Arkansas for Medical Sciences, USA Anne-Marie Demers, Desmond...
19 Feb 2015
TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes...
8 Sep 2014
Moxifloxacin Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with...
22 Apr 2014
TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved...
11 Mar 2014
Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones . EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575 A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis...
9 Sep 2013
By: Shashank Gupta ( sgupta33@jhmi.edu ) In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model. Investigators at Johns Hopkins School of Medicine have found that adding...
29 Jul 2013
Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...
16 Jul 2013
Source: http://www.bloomberg.com/article/2013-07-17/adCNbBPYeTyM.html Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and...
8 Jul 2013
Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB) . Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a...
30 Jun 2013
Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...
25 Apr 2013
Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access , 2) on adaptive clinical trial designs , and 3) on pediatric drug development needs . The full...
3 Feb 2013
The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s...
26 Nov 2012
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Below are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug...
21 Oct 2012
This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug development and the growing number of TB trials and trials...

Pages